Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors
Anticancer Research · 2026-08 · 46 (8) · 4489-4497
DOI: 10.21873/anticanres.18305 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Anticancer Research, online erschienen am 29.07.2026. Verfasst von Shimpei Yamashita und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Wakayama Medical University, Wakayama, Japan; keito608@wakayama-med.ac.jp. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Wakayama Medical University, Wakayama, Japan; keito608@wakayama-med.ac.jp.
- Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
- Department of Urology, Kurume University School of Medicine, Kurume, Japan.
- Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
- Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Japan.
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Zitieren
APA
Yamashita, S., Yamasaki, T., Ueda, K., Tomida, R., Toyoda, S., Iwamoto, H., Miyake, M., Tomisaki, I., Morizane, S., & Kohjimoto, Y. (2026). Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors. Anticancer Research, 46(8), 4489-4497. https://doi.org/10.21873/anticanres.18305
Vancouver
Yamashita S, Yamasaki T, Ueda K, Tomida R, Toyoda S, Iwamoto H, et al. Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors. Anticancer Research. 2026;46(8):4489-4497. doi:10.21873/anticanres.18305
BibTeX
@article{Yamashita2026,
author = {Yamashita, Shimpei and Yamasaki, Takeshi and Ueda, Kosuke and Tomida, Ryotaro and Toyoda, Shingo and Iwamoto, Hiroaki and Miyake, Makito and Tomisaki, Ikko and Morizane, Shuichi and Kohjimoto, Yasuo},
title = {Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors},
journal = {Anticancer Research},
year = {2026},
volume = {46},
number = {8},
pages = {4489--4497},
doi = {10.21873/anticanres.18305}
}
EUVIMED